Immune-mediated liver injury induced by PD-1/PD-L1 checkpoint inhibitors is different from idiosyncratic drug-induced liver injury

被引：0
|
作者：
Wang, Yan [1 ]
Meng, Yao [1 ]
Zhang, Mengmeng [1 ]
Guo, Tiantian [1 ]
Chen, Wei [1 ]
Liu, Liwei [2 ]
Zhao, Xinyan [1 ]
机构：
[1] Capital Med Univ, Beijing Friendship Hosp, Liver Res Ctr, Natl Clin Res Ctr Digest Dis,Key Lab Translat Med, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Youan Hosp, Dept Liver Dis 4, Difficult & Complicated Liver Dis & Artificial Li, Beijing, Peoples R China
来源：
JOURNAL OF HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
SAT-326
引用
收藏
页码：S121 / S121
页数：1
相关论文
共 50 条
  • [41] Idiosyncratic Drug-Induced Liver Injury: A Short Review
    Yamashita, Yo-ichi
    Imai, Katsunori
    Mima, Kosuke
    Nakagawa, Shigeki
    Hashimoto, Daisuke
    Chikamoto, Akira
    Baba, Hideo
    HEPATOLOGY COMMUNICATIONS, 2017, 1 (06) : 494 - 500
  • [42] The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury
    Fontana, Robert J.
    Bjornsson, Einar S.
    Reddy, Rajender
    Andrade, Raul J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (08) : 2088 - 2099
  • [43] Uncommon Presentations of Idiosyncratic Drug-Induced Liver Injury
    Raj Vuppalanchi
    Marwan Ghabril
    Current Hepatology Reports, 2018, 17 (3) : 254 - 259
  • [44] Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
    Anand, Kartik
    Sahu, Geetanjali
    Burns, Ethan
    Ensor, Allyne
    Ensor, Joe
    Pingali, Sai Ravi
    Subbiah, Vivek
    Iyer, Swaminathan P.
    ESMO OPEN, 2020, 5 (04)
  • [45] PD-1/PD-L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)
    Tang, Quanying
    Zhao, Shikang
    Zhou, Ning
    He, Jinling
    Zu, Lingling
    Liu, Tingwen
    Song, Zuoqing
    Chen, Jun
    Peng, Ling
    Xu, Song
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2023, 62 (04)
  • [46] Drug-Induced Liver Injury and Immune Checkpoint Inhibitor-Induced Hepatitis
    Bartl S.
    Dinkhauser P.
    Hofer H.
    Journal für Gastroenterologische und Hepatologische Erkrankungen, 2021, 19 (2) : 34 - 43
  • [47] The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
    Tang, Qing
    Chen, Yun
    Li, Xiaojuan
    Long, Shunqin
    Shi, Yao
    Yu, Yaya
    Wu, Wanyin
    Han, Ling
    Wang, Sumei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [48] Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?
    Konstantinidou, Markella
    Zarganes-Tzitzikas, Tryfon
    Magiera-Mularz, Katarzyna
    Holak, Tad A.
    Domling, Alexander
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2018, 57 (18) : 4840 - 4848
  • [49] PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
    Yang, Tianrui
    Kong, Ziren
    Ma, Wenbin
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (02) : 546 - 553
  • [50] Macrocyclic Peptide Inhibitor of PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Kuska, Katarzyna
    Skalniak, Lukasz
    Grudnik, Przemyslaw
    Musielak, Bogdan
    Plewka, Jacek
    Kocik, Justyna
    Stec, Malgorzata
    Weglarczyk, Kazimierz
    Sala, Dominik
    Wladyka, Benedykt
    Siedlar, Maciej
    Holak, Tad A.
    Dubin, Grzegorz
    ADVANCED THERAPEUTICS, 2021, 4 (02)
12345